Literature DB >> 18257089

Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy?

Sarah A McLaughlin1, Michelle Stempel, Elizabeth A Morris, Laura Liberman, Tari A King.   

Abstract

BACKGROUND: Sentinel lymph node biopsy (SLNB) in the setting of prophylactic mastectomy (PM) remains controversial. In the current study, recent experience with PM was described and the value of preoperative magnetic resonance imaging (MRI) was analyzed in selecting patients for PM with or without SLNB.
METHODS: Between January 1999 and January 2006, 529 patients underwent 613 PMs. Both preoperative magnetic resonance imaging (MRI) and SLNB were performed selectively at the discretion of the surgeon.
RESULTS: Occult cancer was identified in 33 of 613 PMs (5%) (10 invasive and 23 ductal carcinoma in situ cases). PM with SLNB was performed in 393 of 529 patients (74%), 178 of whom underwent MRI. Of these, occult cancer was found in 6 of 178 patients (3%), all of whom had negative SLNB. Preoperative MRI was concordant with PM in 4 of 6 cases with occult carcinoma. The remaining 215 of 393 patients (55%) underwent PM with SLNB without MRI. Occult cancer was found in 18 of 215 patients (8%); 3 had positive SLNB. Overall, PM with SLNB spared 4 of 393 patients (1%) from axillary lymph node dissection (ALND). Among 136 patients undergoing PM alone, 57 had preoperative MRI. MRI detected 5 cancers and PM revealed an additional 4 occult carcinomas not detected by MRI. Overall, 9 of 136 patients (7%) undergoing PM alone were found to have occult cancer, 3 of which were invasive, raising the decision of reoperation with ALND.
CONCLUSIONS: Occult cancer was identified in 5% of PMs. PM with or without SLNB spared only 4 of 393 patients (1%) from undergoing ALND, whereas PM alone identified unsuspected invasive disease in 3 of 136 patients (2%). When performed, MRI accurately ruled out the presence of an invasive cancer in the prophylactic breast, suggesting that MRI can be used to select patients for PM without SLNB. Copyright (c) 2008 American Cancer Society.

Entities:  

Mesh:

Year:  2008        PMID: 18257089     DOI: 10.1002/cncr.23298

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  Meta-analysis of sentinel lymph node biopsy at the time of prophylactic mastectomy of the breast.

Authors:  Wen-Bin Zhou; Xiao-An Liu; Jun-Cheng Dai; Shui Wang
Journal:  Can J Surg       Date:  2011-10       Impact factor: 2.089

2.  Sentinel lymph node biopsy at the time of mastectomy does not increase the risk of lymphedema: implications for prophylactic surgery.

Authors:  Cynthia L Miller; Michelle C Specht; Melissa N Skolny; Lauren S Jammallo; Nora Horick; Jean O'Toole; Suzanne B Coopey; Kevin Hughes; Michele Gadd; Barbara L Smith; Alphonse G Taghian
Journal:  Breast Cancer Res Treat       Date:  2012-09-01       Impact factor: 4.872

3.  The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study.

Authors:  Sara Câmara; Daniela Pereira; Saudade André; Beatriz Mira; Fátima Vaz; Rodrigo Oom; José Carlos Marques; João Leal de Faria; Catarina Rodrigues Dos Santos
Journal:  Int J Breast Cancer       Date:  2018-01-01

4.  The value of breast MRI in high-risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: Is there a role to choose wisely patients for sentinel node biopsy?

Authors:  Vivianne Freitas; Pavel Crystal; Supriya R Kulkarni; Sandeep Ghai; Karina Bukhanov; Jaime Escallon; Anabel M Scaranelo
Journal:  Cancer Med       Date:  2016-03-18       Impact factor: 4.452

5.  High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan.

Authors:  Hideko Yamauchi; Megumi Okawa; Shiro Yokoyama; Chizuko Nakagawa; Reiko Yoshida; Koyu Suzuki; Seigo Nakamura; Masami Arai
Journal:  Breast Cancer Res Treat       Date:  2018-09-10       Impact factor: 4.872

6.  De-escalating axillary surgery in early-stage breast cancer.

Authors:  Eliza H Hersh; Tari A King
Journal:  Breast       Date:  2021-12-15       Impact factor: 4.254

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.